198 related articles for article (PubMed ID: 35982031)
1. BET inhibitors: an updated patent review (2018-2021).
Chen H; Liu Z; Zheng L; Wang R; Shi L
Expert Opin Ther Pat; 2022 Sep; 32(9):953-968. PubMed ID: 35982031
[TBL] [Abstract][Full Text] [Related]
2. Successes and challenges in the development of BD1-selective BET inhibitors: a patent review.
Viviano M; Cipriano A; Fabbrizi E; Feoli A; Castellano S; Sbardella G; Mai A; Milite C; Rotili D
Expert Opin Ther Pat; 2024 Mar; ():1-17. PubMed ID: 38465537
[TBL] [Abstract][Full Text] [Related]
3. A patent review of EZH2 inhibitors from 2017 and beyond.
Wan G; Feng H; Su C; Zhu Y; Zhang L; Zhang Q; Yu L
Expert Opin Ther Pat; 2023 Apr; 33(4):293-308. PubMed ID: 37095742
[TBL] [Abstract][Full Text] [Related]
4. Targeting the epigenetic reader "BET" as a therapeutic strategy for cancer.
Wahi A; Manchanda N; Jain P; Jadhav HR
Bioorg Chem; 2023 Nov; 140():106833. PubMed ID: 37683545
[TBL] [Abstract][Full Text] [Related]
5. BET bromodomain inhibitors: a patent review.
Garnier JM; Sharp PP; Burns CJ
Expert Opin Ther Pat; 2014 Feb; 24(2):185-99. PubMed ID: 24261714
[TBL] [Abstract][Full Text] [Related]
6. Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development.
Chen J; Tang P; Wang Y; Wang J; Yang C; Li Y; Yang G; Wu F; Zhang J; Ouyang L
J Med Chem; 2022 Apr; 65(7):5184-5211. PubMed ID: 35324195
[TBL] [Abstract][Full Text] [Related]
7. BET Inhibitors as Anticancer Agents: A Patent Review.
Ali I; Choi G; Lee K
Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):340-364. PubMed ID: 28786345
[TBL] [Abstract][Full Text] [Related]
8. Role of bromodomain and extraterminal (BET) proteins in prostate cancer.
Mandl A; Markowski MC; Carducci MA; Antonarakis ES
Expert Opin Investig Drugs; 2023 Mar; 32(3):213-228. PubMed ID: 36857796
[TBL] [Abstract][Full Text] [Related]
9. A patent review of BRD4 inhibitors (2013-2019).
Lu T; Lu W; Luo C
Expert Opin Ther Pat; 2020 Jan; 30(1):57-81. PubMed ID: 31815566
[No Abstract] [Full Text] [Related]
10. The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders.
Li P; Li B; Yang N; Xu T; Zheng Z
Expert Opin Ther Pat; 2023; 33(7-8):477-492. PubMed ID: 37873645
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation-induced profibrotic fibroblast responses.
Liu CS; Rioja I; Bakr A; Veldwijk MR; Sperk E; Herskind C; Weichenhan D; Prinjha RK; Plass C; Schmezer P; Popanda O
Int J Cancer; 2022 Jul; 151(2):275-286. PubMed ID: 35239184
[TBL] [Abstract][Full Text] [Related]
12. Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer.
Slavish PJ; Chi L; Yun MK; Tsurkan L; Martinez NE; Jonchere B; Chai SC; Connelly M; Waddell MB; Das S; Neale G; Li Z; Shadrick WR; Olsen RR; Freeman KW; Low JA; Price JE; Young BM; Bharatham N; Boyd VA; Yang J; Lee RE; Morfouace M; Roussel MF; Chen T; Savic D; Guy RK; White SW; Shelat AA; Potter PM
Cancer Res; 2020 Sep; 80(17):3507-3518. PubMed ID: 32651255
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
[TBL] [Abstract][Full Text] [Related]
14. BETting on next-generation bromodomain inhibitors.
Collins MK; Chau CH; Price DK; Figg WD
Am J Clin Exp Urol; 2020; 8(4):129-132. PubMed ID: 32929408
[TBL] [Abstract][Full Text] [Related]
15. BET inhibitors in cancer therapeutics: a patent review.
Ghoshal A; Yugandhar D; Srivastava AK
Expert Opin Ther Pat; 2016; 26(4):505-22. PubMed ID: 26924192
[TBL] [Abstract][Full Text] [Related]
16. Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases.
Morgado-Pascual JL; Rayego-Mateos S; Tejedor L; Suarez-Alvarez B; Ruiz-Ortega M
Front Pharmacol; 2019; 10():1315. PubMed ID: 31780938
[TBL] [Abstract][Full Text] [Related]
17. RVX-297- a novel BD2 selective inhibitor of BET bromodomains.
Kharenko OA; Gesner EM; Patel RG; Norek K; White A; Fontano E; Suto RK; Young PR; McLure KG; Hansen HC
Biochem Biophys Res Commun; 2016 Aug; 477(1):62-67. PubMed ID: 27282480
[TBL] [Abstract][Full Text] [Related]
18. Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation.
Gilan O; Rioja I; Knezevic K; Bell MJ; Yeung MM; Harker NR; Lam EYN; Chung CW; Bamborough P; Petretich M; Urh M; Atkinson SJ; Bassil AK; Roberts EJ; Vassiliadis D; Burr ML; Preston AGS; Wellaway C; Werner T; Gray JR; Michon AM; Gobbetti T; Kumar V; Soden PE; Haynes A; Vappiani J; Tough DF; Taylor S; Dawson SJ; Bantscheff M; Lindon M; Drewes G; Demont EH; Daniels DL; Grandi P; Prinjha RK; Dawson MA
Science; 2020 Apr; 368(6489):387-394. PubMed ID: 32193360
[TBL] [Abstract][Full Text] [Related]
19. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
Taniguchi Y
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
[TBL] [Abstract][Full Text] [Related]
20. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
